ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes

Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue prote...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Med
Päätekijät: Brines, Michael, Dunne, Ann N, van Velzen, Monique, Proto, Paolo L, Ostenson, Claes-Goran, Kirk, Rita I, Petropoulos, Ioannis N, Javed, Saad, Malik, Rayaz A, Cerami, Anthony, Dahan, Albert
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: ScholarOne 2015
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365069/
https://ncbi.nlm.nih.gov/pubmed/25387363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2119/molmed.2014.00215
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia